Orforglipron is a once-daily tablet that acts on the GLP-1 receptor and is not a peptide. In a 72-week phase 3 trial of 3,127 adults with obesity, weight fell 11.2% on the 36 mg dose against 2.1% on placebo [1]. Everything else in this library is a peptide, either injected or put into a tablet with an absorption enhancer to survive the stomach. Orforglipron is neither. Being a small molecule is a chemistry difference with practical consequences: no cold chain, no needle, and none of the food-timing rules the existing pill requires. That last one is covered in what the pill actually does.
What the trial did
ATTAIN-1 was a phase 3, multinational, double-blind trial in adults who had obesity and did not have diabetes. Patients were randomized in a 3:3:3:4 ratio to once-daily orforglipron at 6 mg, 12 mg or 36 mg, or to placebo, alongside diet and activity advice, for 72 weeks. The primary endpoint was percent change in body weight at week 72, analyzed in the intention-to-treat population.
What it found
Among the 3,127 patients randomized, mean weight change at 72 weeks was −7.5% at 6 mg (95% CI −8.2 to −6.8). The 12 mg dose gave −8.4% (95% CI −9.1 to −7.7). The 36 mg dose gave −11.2% (95% CI −12.0 to −10.4). Placebo gave −2.1% (95% CI −2.8 to −1.4).
The thresholds are the more legible version of the same result. On 36 mg, 54.6% of patients lost 10% or more of their body weight, 36.0% lost 15% or more and 18.4% lost 20% or more. The placebo figures were 12.9%, 5.9% and 2.8%. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved against placebo as well.
How it sits beside the other pill
The nearest comparison is oral semaglutide, and it is not a randomized one. At 25 mg over 64 weeks, oral semaglutide produced a mean weight reduction of 13.6% against 2.2% on placebo in adults with overweight or obesity [2]. Different trial, different population, different duration.
A network meta-analysis of drugs for overweight and obesity places the whole class rather than ranking these two [3]. Its finding is that the agents taking off the most weight are also the ones people stop soonest. Orforglipron’s discontinuation figures below are the same trade in miniature.
What it costs in tolerability
Adverse events led to discontinuation in 5.3% to 10.3% of patients across the three orforglipron groups, against 2.7% on placebo. The most common were gastrointestinal and mostly mild to moderate — the same pattern the injected drugs produce, described in titration and nausea. The dose-response runs both ways: the arm that lost most weight was also the arm people left most often.
Where a reader will meet it
It is already being sold. Several storefronts tracked here list the branded tablet. It is usually routed through the manufacturer’s own pharmacy with a membership charged beside it, which makes the advertised medication figure only part of the bill. That structure is the subject of what sellers will not tell you. The dose question applies here as much as anywhere. 36 mg is the dose that produced the headline, and a seller quoting a starter price is quoting a different rung. Which sellers publish the rungs at all is counted in who publishes a dose ladder.